Cellebrite DI Ltd. (NASDAQ:CLBT) Sees Significant Increase in Short Interest

Cellebrite DI Ltd. (NASDAQ:CLBT) saw a significant growth in short interest in March. As of March 15th, there was short interest totalling 1,280,000 shares, a growth of 19.6% from the February 28th total of 1,070,000 shares. Approximately 1.2% of the company’s shares are sold short. Based on an average daily volume of 1,830,000 shares, the short-interest ratio is presently 0.7 days.

Cellebrite DI Trading Up 3.0 %

Shares of NASDAQ CLBT opened at $19.83 on Thursday. The stock has a market cap of $4.75 billion, a P/E ratio of -14.27, a PEG ratio of 4.27 and a beta of 1.52. The business’s fifty day simple moving average is $20.62 and its 200-day simple moving average is $19.94. Cellebrite DI has a 12-month low of $10.25 and a 12-month high of $26.30.

Cellebrite DI (NASDAQ:CLBT) last posted its quarterly earnings results on Thursday, February 13th. The company reported $0.07 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). Cellebrite DI had a negative net margin of 70.54% and a positive return on equity of 58.70%. On average, equities analysts forecast that Cellebrite DI will post 0.3 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on CLBT shares. Needham & Company LLC reaffirmed a “buy” rating and issued a $28.00 price objective on shares of Cellebrite DI in a research note on Wednesday. JPMorgan Chase & Co. raised their target price on Cellebrite DI from $24.00 to $28.00 and gave the company an “overweight” rating in a report on Tuesday, February 11th. Finally, Lake Street Capital boosted their price target on shares of Cellebrite DI from $17.00 to $26.00 and gave the stock a “buy” rating in a research note on Friday, February 14th. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $23.43.

Institutional Investors Weigh In On Cellebrite DI

A number of large investors have recently modified their holdings of the company. Axon Enterprise Inc. acquired a new position in shares of Cellebrite DI during the fourth quarter worth $198,270,000. FMR LLC increased its holdings in shares of Cellebrite DI by 89.1% in the 4th quarter. FMR LLC now owns 10,621,344 shares of the company’s stock valued at $233,988,000 after acquiring an additional 5,004,587 shares during the last quarter. True Wind Capital Management L.P. raised its position in shares of Cellebrite DI by 18.2% during the 4th quarter. True Wind Capital Management L.P. now owns 13,861,007 shares of the company’s stock worth $305,358,000 after acquiring an additional 2,130,386 shares in the last quarter. Invesco Ltd. purchased a new stake in Cellebrite DI during the fourth quarter worth approximately $32,700,000. Finally, Principal Financial Group Inc. purchased a new position in Cellebrite DI in the third quarter valued at approximately $23,402,000. 45.88% of the stock is owned by hedge funds and other institutional investors.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.